On September 11, 2025, the U.S. Food and Drug Administration (FDA) issued new guidance for the development of therapeutic protein biosimilars, focusing on comparative analytical assessment and quality ...
Add Yahoo as a preferred source to see more of our stories on Google. FDA Commissioner Marty Makary speaks in the Oval Office at the White House on May 05, 2025. (Anna Moneymaker via Getty Images) ...
Biosimilar formulation development requires navigating around scientific, regulatory, and legal challenges, according to Sung ...
Biological products, or biologics, are large, complex molecules produced in living systems such as therapeutic proteins, antibodies, and gene- or cell-based therapies. Under the Public Health Service ...
One week after releasing its 11-part biosimilar action plan, the US Food and Drug Administration (FDA) announced it will hold a public hearing to gather input on how it can facilitate the development ...
Currently, the global biosimilars market includes monoclonal antibody (mAb) biosimilars, insulins, interferons, erythropoietins, filgrastim, somatropin and follicle-stimulating hormone. Of these, the ...
Biosimilars are driving down drug costs, expanding access to critical treatments, and creating space for future innovation. In this episode, Linda Choi MacDonald, EVP and Global Head of Commercial at ...
The global unit will be headed by Armin Metzger, who will join Sandoz on April 1, 2026. Metzger, who will be president of biosimilar development, manufacturing and supply, joins Sandoz from ...
Basel, July 20, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a ...
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ...
Biosimilars have yet to achieve their main purpose: to reduce the costs of complex biological drugs, as generics do for small molecules. Multiple barriers, from development costs to the contracting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results